Antonio Colombo

IMPACT OF GENDER ON PATTERNS OF DUAL ANTIPLATELET THERAPY CESSATION AND NON-ADHERENCE: ONE-YEAR RESULTS FROM THE PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS (PARIS), AN OBSERVATIONAL SINGLE-ARM STUDY

Multiple clinical and sociodemographic factors are associated with adherence to dual antiplatelet therapy (DAPT) post percutaneous coronary intervention (PCI). Studies have shown women to have higher rates of adverse events after PCI. Whether this increased risk is attributable to DAPT cessation is

WHITE BLOOD CELL COUNT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE CONTEMPORARY ERA: INSIGHTS FROM THE PARIS STUDY

Steg, PG; Weisz, G; Witzenbichler, B; Henry, TD; Kini, AS; Stuckey, T; Cohen, DJ; Iakovou, I; Dangas, G; Aquino, MB; Sartori, S; Chieffo, A; Moliterno, DJ; Colombo, A; Mehran, R (2017) White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circulation Cardiovascular interventions, 10 (9). ISSN 1941-7640 DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.117.004981

EFFECT OF BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN IN TRANSCATHETER AORTIC VALVE REPLACEMENT WITH SELF-EXPANDING VALVES: FROM THE BRAVO-3 RANDOMIZED TRIAL

Background: Selection of valve and sheath type may impact on procedural complications in transcatheter aortic valve replacement (TAVR). Whether bivalirudin (BIV) reduces bleeding compared with unfractionated heparin (UFH) specifically with self-expanding (SE) TAVR is unknown. We sought to compare

EFFECT OF BIVALIRUDIN VERSUS HEPARIN IN A CONTEMPORARY TAVR POPULATION OF WOMEN: RESULTS FROM THE BRAVO 3 RANDOMIZED TRIAL

Women experience greater bleeding and vascular complications in transcatheter aortic valve replacement (TAVR). Whether bivalirudin lowers bleeding risk in women compared with unfractionated heparin (UFH) is unknown.nnBRAVO 3 was a randomized multicenter trial comparing transfemoral TAVR with

PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY

Demographic and socioclinical factors affect adherence to dual anti-platelet therapy (DAPT) after percutaneous coronary intervention (PCI). DAPT cessation has been shown to increase stent thrombosis risk, recurrent myocardial infarction, and death. We investigated correlates of DAPT non-adherence